Small Cap Losers: ENOB, ZIOP, ALT
3:15 pm Tuesday, September 28th, 2021
Enochian Biosciences Inc (NASDAQ: ENOB) dips to its lowest levels in about a month on moderately elevated volume. Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company’s lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine.
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) announced a restructuring to enable co to advance its TCR program and extend its cash runway into the first half of 2023; co has reduced its personnel by over 50%. Also announced that the first patient in its TCR-T Library Phase I/II trial is expected to be dosed in the first half of 2022 after experiencing delays caused by inadequate resources at its contract manufacturer; co is committed to having internal manufacturing capabilities operational in the first half of 2022.
Altimmune Inc (NASDAQ: ALT) sees volatility after co announced results from its 12-week, Phase 1 trial of pemvidutide in overweight and obese volunteers. Subjects receiving pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at 12 weeks at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, vs the placebo group’s mean weight loss of 1.6%. No discontinuations due to adverse events were reported; one patient experienced elevated ALT levels that resolved after a pause in dosing. Among pemvidutide development plans, co intends to file an IND application in obesity in Q4. The stock has recovered off of session lows.
